For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com  Inclusion Criteria:  Confirmation of the following for Acute Myeloid Leukemia (AML) Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. ECOG 3 is allowed if participants are 18 to 74 years old with comorbidities Agree to serial bone marrow aspirate/biopsies  Exclusion Criteria:  Suspected or proven to have acute promyelocytic leukemia based on morphology, immunophenotype, molecular assay, or karyotype Received prior hypomethylating agent (HMA) therapy for myelodysplastic syndromes/Chronic myelomonocytic leukemia then develop AML within 4 months of discontinuing the HMA therapy Prior history of malignancy unless the subject has been free of the disease for ≥ 1 year prior to the start of study treatment  Other protocol-defined inclusion/exclusion criteria apply